SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Sequenta, Inc. today announced publication of a study demonstrating that the company’s ultra-sensitive sequencing-based minimal residual disease (MRD) detection technology, available clinically as the ClonoSIGHT™ test, provides important prognostic information in multiple myeloma. Both time to progression (TTP) and overall survival (OS) were shown to be significantly longer in MRD-negative patients compared those who were MRD-positive (n=110; median TTP: 80 months vs. 31 months, p<0.0001; median OS: not reached vs. 81 months, p=0.02).
Help employers find you! Check out all the jobs and post your resume.
